Specific Bacterial Species and Metabolite That Improves Immune Checkpoint Inhibitor Therapy Efficacy
US-2020129570-A1 · Apr 30, 2020 · US
Antitumor effect potentiator
US2022000949A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022000949-A1 |
| Application number | US-201917279322-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 25, 2019 |
| Priority date | Sep 25, 2018 |
| Publication date | Jan 6, 2022 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.
First claim
Opening claim text (preview).
1 . An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, the agent comprising: active ingredients comprising a probiotic and a prebiotic. 2 . The agent of claim 1 , wherein the probiotic is one or more selected from the group consisting of bacteria of the genus Lactobacillus and bacteria of the genus Bifidobacterium. 3 . The agent of claim 1 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei and Bifidobacterium breve. 4 . The agent of claim 1 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei YIT9029 (FERM BP-1366) and Bifidobacterium breve YIT12272 (FERM BP-11320). 5 . The agent of claim 1 , wherein the prebiotic is a galactooligosaccharide. 6 . The agent of claim 1 , wherein the prebiotic is a galactooligosaccharide comprising β-1,4 galactosyllactose as a main ingredient. 7 . The agent of claim 1 , wherein the immune checkpoint inhibitor is one or more selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and a PD-1 antagonist. 8 . An agent suitable for activating tumor immunity, the agent comprising active ingredients comprising: a probiotic; a prebiotic; and an immune checkpoint inhibitor. 9 . The agent of claim 8 , wherein the tumor immunity is activated by reversing immunosuppressive state mediated by regulatory T cells and/or activating NK cells. 10 - 17 . (canceled) 18 . A method for potentiating an antitumor effect of an immune checkpoint inhibitor, the method comprising: administering an effective amount a probiotic and a prebiotic to a subject in need thereof. 19 . A method for activating tumor immunity, the method comprising: administering an effective amount a probiotic, a prebiotic, and an immune checkpoint inhibitor to a subject in need thereof. 20 . The method of claim 18 , wherein the probiotic is one or more selected from the group consisting of bacteria of the genus Lactobacillus and bacteria of the genus Bifidobacterium. 21 . The method of claim 19 , wherein the probiotic is one or more selected from the group consisting of bacteria of the genus Lactobacillus and bacteria of the genus Bifidobacterium. 22 . The method of claim 18 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei and Bifidobacterium breve. 23 . The method of claim 19 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei and Bifidobacterium breve. 24 . The method of claim 18 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei YIT9029 (FERM BP-1366) and Bifidobacterium breve YIT12272 (FERM BP-11320). 25 . The method of claim 19 , wherein the probiotic is one or more selected from the group consisting of Lactobacillus casei YIT9029 (FERM BP-1366) and Bifidobacterium breve YIT12272 (FERM BP-11320). 26 . The method of claim 18 , wherein the prebiotic is a galactooligosaccharide. 27 . The method of claim 19 , wherein the prebiotic is a galactooligosaccharide.
Assignees
Inventors
Classifications
against CD28 or CD152 · CPC title
- A61K35/747Primary
Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title
Immunostimulants · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2022000949A1 cover?
- An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.
- Who is the assignee on this patent?
- Nat Cerebral & Cardiovascular Ct, Yakult Honsha Kk
- What technology area does this patent fall under?
- Primary CPC classification A61K35/747. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jan 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).